Oncorus

Oncorus is an American biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients. Oncorus serves the healthcare sector in the United States.

P/E

Net profit

P/B

Book value

P/FCF

FCF

Yield

Growth potential

Report period	2018	2019	2020	2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2018	2019	2020	2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Report period	2018	2019	2020	2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Report period	2018	2019	2020	2021
ROA
ROE
ROS

Oncorus news

04.05.2022

Oncorus' GAAP loss for 3 months of 2022 was $17.78 million, up 40.4% from $12.663 million in the previous year.

Source:

investors.oncorus.com

09.03.2022

Oncorus' GAAP loss for 2021 was $64.762 million, up 34.1 percent from $48.299 million the previous year.

Source:

investors.oncorus.com

03.11.2021

Oncorus' GAAP loss for 9M 2021 was $44.919 million, up 22.3% from $36.732 million in the prior year.

Source:

investors.oncorus.com

04.08.2021

Oncorus' GAAP loss for 6M 2021 was $28.191 million, up 63.9% from $17.201 million in the prior year.

Source:

investors.oncorus.com

All Oncorus news

General information

Company name	Oncorus
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address	50 Hampshire Street Suite 401 Cambridge, MA 02139 United States
Website	investors.oncorus.com
Information disclosure	www.sec.gov

Oncorus

Oncorus balance sheet

Oncorus cash flows

Oncorus multipliers

Oncorus profitability

Oncorus dividend policy